Asensus Surgical, Inc. (ASXC) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $1 million versus the consensus estimate...
Axsome Therapeutics (NASDAQ:AXSM) +20% on raising $23.3M (NYSE:MMM) under existing ATM facility.Pyxis Tankers (NASDAQ:PXS) +13%.Taoping (NASDAQ:TAOP) +11% to acquire 51% of...
The field of surgery is being largely shaped by breakthroughs in computer technology and AI. One of the latest healthcare IT trends to watch out for is robot-assisted surgery. This...
Investors in TransEnterix, Inc. (NYSE:TRXC) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 18, 2019 $3.00 Call had...
Asensus Surgical, Inc. is a medical device company that is digitizing the interface between the surgeon and the patient through Performance-Guided Surgery. The Company is focused on the market development and commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery (MIS). The Senhance System is a digital and multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits, such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation, including three-millimeter (mm) micro laparoscopic instruments, five mm articulating instruments, eye-sensing camera control and fully reusable standard instruments to patients around the world. Its Senhance System is used in Europe for adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations. It is also available in the United States, Japan, Taiwan and Russia.
|Average||4.000 (+788.89% Upside)|
|No. of Analysts||1|